Pfizer, Humedica ink real-world data pact

Share this article:
Geno Germano
Geno Germano

Pfizer continues to dive deeper into real-world data. In December the drugmaker and clinical data outfit Humedica jointly announced their intent to collaborate on studies examining the effectiveness of treatments.

The research will focus on the US for now, says a source, and will draw on Humedica's NorthStar data repository. NorthStar aggregates EHR data directly from providers, capturing medications, lab results and physician notes via natural-language processing, among other data points. (All information is de-identified, says Humedica.) The aim is to let pharma see how physicians are adopting brands.

Humedica will apply “Big Data solutions across the continuum of care,” said Michael Weintraub, Humedica's president and CEO, in the statement.

“The collaboration with Humedica will provide us with powerful information about healthcare delivery and patient outcomes,” added Geno Germano, president and general manager, Pfizer Specialty Care Business Unit.

The deal follows Pfizer's 2011 pact with Humana, also involving real-world data and comparative-effectiveness research, and underscores a desire among life science firms to harness Big Data to enhance outcomes.

Pacts to build up real-world data stores have been struck by AstraZeneca, which signed up with IMS Health and Wellpoint; Merck, who's working with online research platform PatientsLikeMe; and Sanofi, which teamed with Medco.
Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...